NEWS

Coulter Partners places Director of Clinical Operations at BerGenBio

Coulter Partners has placed Viki Wills as Director of Clinical Operations at BerGenBio, a clinical stage biopharmaceutical company focused on developing first-in-class drugs for aggressive cancers. The company is a world leader in understanding the biology of the epithelial-mesenchymal transition (EMT). This natural cellular programme is, when it occurs inappropriately, implicated in the development of immune-evasion and acquired drug-resistance in cancer cells. When EMT is inhibited with BerGenBio’s drug candidates the cancer cells become visible and sensitive to the body’s immune system and the effectiveness of commonly used cancer drugs is restored.

As we advance our clinical pipeline, this role will provide Viki with a tremendous opportunity to make a difference and contribute to generating value for patients, as well as for the business and its shareholders. I am delighted to welcome her on board and I would like to thank all those at Coulter Partners who were involved in the search – an outstanding team, whose professionalism has impressed us throughout,” comments BerGenBio’s Chief Executive Officer, Richard Godfrey.

BerGenBio asked Coulter Partners to conduct a search to identify top-calibre individuals who could be responsible for the execution of clinical development of the company’s assets, deliver proof of concept and create a package ready for licensing or to move into phase III. The role required someone with a hands-on approach and extensive direct experience of all the aspects of Clinical Operations Management. Coulter Partners employed psychometric assessment to assist in shortlisting the best possible candidates for the role, under the supervision of their specialists in occupational psychology and focused in particular on how candidates might fit into the client’s organisational culture.

Viki Wills joins BerGenBio from Daiichi Sankyo where she was also Director of Clinical Operations in the field of oncology. She draws on extensive pharmaceutical and biotechnology industry experience in clinical development, funding acquisition and KOL relationship management, gained with other global drug development organisations. BerGenBio has been advancing its clinical pipeline – a combination of own clinical trials managed in partnership with CROs; and investigator led studies, requiring study monitoring from BerGenBio. As Director of Clinical Operations, Viki will manage the team and take operational responsibilities for the clinical studies and work conducted through CROs and a dedicated team. She will represent the company externally with investigators, regulators and financial stakeholders.